- Home
- MOS vs ROIV Comparison
MOS vs ROIV Comparison
Compare MOS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- ROIV
- Stock Information
- Founded
- MOS 1987
- ROIV 2014
- Country
- MOS United States
- ROIV United Kingdom
- Employees
- MOS N/A
- ROIV N/A
- Industry
- MOS Agricultural Chemicals
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- MOS Industrials
- ROIV Health Care
- Exchange
- MOS Nasdaq
- ROIV Nasdaq
- Market Cap
- MOS 11.2B
- ROIV 7.8B
- IPO Year
- MOS 2004
- ROIV N/A
- Fundamental
- Price
- MOS $36.16
- ROIV $11.40
- Analyst Decision
- MOS Buy
- ROIV Buy
- Analyst Count
- MOS 12
- ROIV 4
- Target Price
- MOS $35.33
- ROIV $17.50
- AVG Volume (30 Days)
- MOS 5.3M
- ROIV 7.9M
- Earning Date
- MOS 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- MOS 2.45%
- ROIV N/A
- EPS Growth
- MOS N/A
- ROIV N/A
- EPS
- MOS 1.15
- ROIV N/A
- Revenue
- MOS $11,064,300,000.00
- ROIV $29,053,000.00
- Revenue This Year
- MOS $17.03
- ROIV $3.28
- Revenue Next Year
- MOS N/A
- ROIV $156.84
- P/E Ratio
- MOS $31.57
- ROIV N/A
- Revenue Growth
- MOS N/A
- ROIV N/A
- 52 Week Low
- MOS $22.36
- ROIV $8.73
- 52 Week High
- MOS $38.23
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- MOS 51.65
- ROIV 54.55
- Support Level
- MOS $34.88
- ROIV $10.71
- Resistance Level
- MOS $38.23
- ROIV $11.58
- Average True Range (ATR)
- MOS 0.93
- ROIV 0.29
- MACD
- MOS -0.12
- ROIV 0.00
- Stochastic Oscillator
- MOS 37.61
- ROIV 62.16
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.